121 related articles for article (PubMed ID: 26217553)
1. Combination chemotherapy with mitomycin C and methotrexate is active against metastatic HER2-negative breast cancer even after treatment with anthracycline, taxane, capecitabine, and vinorelbine.
Fukuda T; Tanabe M; Kobayashi K; Fukada I; Takahashi S; Iwase T; Ito Y
Springerplus; 2015; 4():376. PubMed ID: 26217553
[TBL] [Abstract][Full Text] [Related]
2. Combination Chemotherapy of Mitomycin C and Methotrexate Was Effective on Metastatic Breast Cancer Resistant to Eribulin, Vinorelbine, and Bevacizumab after Anthracycline, Taxane, and Capecitabine.
Tanabe M
Case Rep Oncol; 2016; 9(2):422-426. PubMed ID: 27721762
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine and vinorelbine combination chemotherapy in anthracycline- and taxane-pretreated advanced breast cancer.
Kim HJ; Kim JS; Seo MD; Oh SY; Oh DY; Kim JH; Lee SH; Kim DW; Im SA; Kim TY; Heo DS; Bang YJ
Cancer Res Treat; 2008 Jun; 40(2):81-6. PubMed ID: 19688053
[TBL] [Abstract][Full Text] [Related]
4. Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes.
Tanabe M; Ito Y; Tokudome N; Sugihara T; Miura H; Takahashi S; Seto Y; Iwase T; Hatake K
Breast Cancer; 2009; 16(4):301-6. PubMed ID: 19205831
[TBL] [Abstract][Full Text] [Related]
5. Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer.
Chen XL; Du F; Hong RX; Wang JY; Luo Y; Li Q; Fan Y; Xu BH
Chin J Cancer; 2016 Apr; 35():39. PubMed ID: 27112139
[TBL] [Abstract][Full Text] [Related]
6. Mitomycin C in combination with vinorelbine in anthracycline- and/or taxane-pretreated patients with metastatic breast cancer.
Schippert C; Warm M; Blohmer JU; du Bois A; Lück HJ
Onkologie; 2012; 35(9):500-4. PubMed ID: 23007147
[TBL] [Abstract][Full Text] [Related]
7. Sequential therapy with capecitabine followed by vinorelbine/cisplatin in patients with anthracycline/taxane-refractory metastatic breast cancer.
Lin PC; Wang WS; Yang MH; Yen CC; Chao TC; Hsiao LT; Chen PM
J Chin Med Assoc; 2006 Jul; 69(7):304-9. PubMed ID: 16903643
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine.
Ito Y; Osaki Y; Tokudome N; Sugihara T; Takahashi S; Iwase T; Hatake K
Breast Cancer; 2009; 16(2):126-31. PubMed ID: 18807123
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
Gilabert M; Bertucci F; Esterni B; Madroszyk A; Tarpin C; Jacquemier J; Extra JM; Viens P; Gonçalves A
Anticancer Res; 2011 Mar; 31(3):1079-86. PubMed ID: 21498742
[TBL] [Abstract][Full Text] [Related]
10. Survival differences observed in metastatic breast cancer patients treated with capecitabine when compared with vinorelbine after pretreatment with anthracycline and taxane.
Verma S; Wong NS; Trudeau M; Joy A; Mackey J; Dranitsaris G; Clemons M
Am J Clin Oncol; 2007 Jun; 30(3):297-302. PubMed ID: 17551309
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Lee SH; Lee J; Park J; Park SH; Lee KE; Lee SI; Nam E; Park JO; Kim K; Jung CW; Park YS; Yoon SS; Kang WK; Lee MH; Park K; Im YH
Med Oncol; 2004; 21(3):223-31. PubMed ID: 15456949
[TBL] [Abstract][Full Text] [Related]
12. All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer.
Tawfik H; Rostom Y; Elghazaly H
Cancer Chemother Pharmacol; 2013 Apr; 71(4):913-9. PubMed ID: 23344713
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS
J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer.
Welt A; von Minckwitz G; Oberhoff C; Borquez D; Schleucher R; Loibl S; Harstrick A; Kaufmann M; Seeber S; Vanhoefer U
Ann Oncol; 2005 Jan; 16(1):64-9. PubMed ID: 15598940
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
Blum JL; Dees EC; Vukelja SJ; Amare M; Gill DP; McMahon RT; Ilegbodu D; Asmar L; O'Shaughnessy JA
Clin Breast Cancer; 2007 Feb; 7(6):465-70. PubMed ID: 17386123
[TBL] [Abstract][Full Text] [Related]
16. Real-world data on the efficacy and safety of weekly oral vinorelbine in breast cancer patients previously treated with anthracycline or taxane-based regimens.
Blancas I; Aguirre E; Morales S; Gonzálvez ML; Servitja S; Díaz N; Del Barco S; Barnadas A; Margelí M; García Carbonero I; Llombart A
Clin Transl Oncol; 2019 Apr; 21(4):459-466. PubMed ID: 30293232
[TBL] [Abstract][Full Text] [Related]
17. Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies.
O'Shaughnessy J; McIntyre K; Schwartzberg L; Wilks S; Puhalla S; Berrak E; Song J; Vahdat L
Springerplus; 2015; 4():532. PubMed ID: 26413438
[TBL] [Abstract][Full Text] [Related]
18. Individualized chemotherapy based on organ selectivity: a retrospective study of vinorelbine and capecitabine for patients with metastatic breast cancer.
Liu XH; Man YN; Cao R; Liu C; Wu XZ
Curr Med Res Opin; 2014 Jun; 30(6):1017-24. PubMed ID: 24528110
[TBL] [Abstract][Full Text] [Related]
19. Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?
Zhang J; Gu SY; Gan Y; Wang ZH; Wang BY; Guo HY; Wang JL; Wang LP; Zhao XM; Hu XC
Cancer Chemother Pharmacol; 2013 Jan; 71(1):103-13. PubMed ID: 23053266
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Diéras V; Miles D; Verma S; Pegram M; Welslau M; Baselga J; Krop IE; Blackwell K; Hoersch S; Xu J; Green M; Gianni L
Lancet Oncol; 2017 Jun; 18(6):732-742. PubMed ID: 28526536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
